How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study

BMC Medical Ethics

Volumn 18, Issue 1, 2017, Pages

  Ma, Yonghui ^a   Yang, Jinqiu ^a   Cui, Bota ^b   Xu, Hongzhi ^c   Xiao, Chuanxing ^c   Zhang, Faming ^b  

^a XIAMEN UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Fecal microbiota transplantation; Informed consent; Research ethics; Risk benefit evaluation

Indexed keywords

AWARENESS; BIOETHICS; CHINA; CLOSTRIDIUM INFECTION; DOCTOR PATIENT RELATION; DONOR; EMOTION; ETHICS; FECAL MICROBIOTA TRANSPLANTATION; GASTROENTEROLOGIST; GASTROENTEROLOGY; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMED CONSENT; PHYSICIAN; PRIVACY; PSYCHOLOGY; QUESTIONNAIRE;

ATTITUDE OF HEALTH PERSONNEL; AWARENESS; BIOETHICAL ISSUES; CHINA; CLOSTRIDIUM INFECTIONS; EMOTIONS; FECAL MICROBIOTA TRANSPLANTATION; GASTROENTEROLOGISTS; GASTROENTEROLOGY; HUMANS; INFORMED CONSENT; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; PRIVACY; SURVEYS AND QUESTIONNAIRES; TISSUE DONORS;

EID: 85019709809     PISSN: None     EISSN: 14726939     Source Type: Journal    
DOI: 10.1186/s12910-017-0200-2     Document Type: Article

References (48)

1. Hurst SA, Hull SC, DuVal G, et al. How physicians face ethical difficulties: a qualitative analysis. J med Ethics. 2005;31(1):7-14. doi:10.1136/jme.2003.005835. [published Online First: Epub Date]
2. Petrof EO, Khoruts A. From stool transplants to next-generation Microbiota therapeutics. Gastroenterology. 2014;146(6):1573-82. doi:10.1053/j.gastro.2014.01.004. [published Online First: Epub Date]
3. Borody TJ, Paramsothy S, Agrawal G. Fecal Microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013;15(8):337. doi:10.1007/s11894-013-0337-1. [published Online First: Epub Date]
4. Brandt LJ. American Journal of gastroenterology lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013;108(2):177-85. doi:10.1038/ajg.2012.450. [published Online First: Epub Date]
5. Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin N am. 2012;41(4):781-803. doi:10.1016/j.gtc.2012.08.008. [published Online First: Epub Date]
6. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium Difficile infection: a systematic review. J Clin Gastroenterol. 2014;48(8):693-702. doi:10.1097/mcg.0000000000000046. [published Online First: Epub Date]
7. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012;107(11):1755; author reply p.55-1756 doi:10.1038/ajg.2012.251[published Online First: Epub Date].
8. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium Difficile infections. Am J Gastroenterol. 2013;108(4):478-98.
9. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat rev Gastroenterol Hepatol. 2012;9(2):88-96. doi:10.1038/nrgastro.2011.244. [published Online First: Epub Date]
10. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal Microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149(1):223-37. doi:10.1053/j.gastro.2015.05.008. [published Online First: Epub Date]
11. Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51-8. doi:10.1111/jgh.12727. [published Online First: Epub Date]
12. Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut microbes. 2016:1-6 doi:10.1080/19490976.2016.1151608 [published Online First: Epub Date].
13. Jung Lee W, Lattimer LDN, Stephen S, et al. Fecal Microbiota transplantation: a review of emerging indications beyond relapsing Clostridium Difficile toxin colitis. Gastroenterol Hepatol. 2015;11(1):24-32.
14. Ma Y, Liu J, Rhodes C, et al. Ethical Issues in Fecal Microbiota Transplantation in Practice. Am J Bioethics. doi: 10.1080/15265161.2017.1299240 [published Online First: Epub Date].
15. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19(7):1506-13. doi:10.1097/MIB.0b013e318281f520. [published Online First: Epub Date]
16. Kahn SA, Gorawara-Bhat R, Rubin DT. Fecal Bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis. 2012;18(4):676-84. doi:10.1002/ibd.21775. [published Online First: Epub Date]
17. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum Infect Dis. 2015;2(1):ofv004. doi:10.1093/ofid/ofv004. [published Online First: Epub Date]
18. Food and Drug Administration. Guidance for industry: Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile iinfection not responsive to standard therapies. 2013; Available at: http://www.fda.gov/biologicsbloodVaccines/Guidancecomplianceregulatoryinformation/Guidances/Vaccines/ucm361379.htm. Accessed 3 Dec 2015.
19. Daloiso V, Minacori R, Refolo P, et al. Ethical aspects of fecal Microbiota transplantation (FMT). Eur Rev Med Pharmacol Sci. 2015;19(17):3173-80.
20. Hawkins AK, O’Doherty KC. “who owns your poop?”: insights regarding the intersection of human microbiome research and the ELSI aspects of biobanking and related studies. BMC med Genet. 2011;4:72. doi:10.1186/1755-8794-4-72. [published Online First: Epub Date]
21. Zapata HJ, Quagliarello VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J am Geriatr soc. 2015;63(4):776-81. doi:10.1111/jgs.13310. [published Online First: Epub Date]
22. W K. The brave new world of DIY faecal transplant. 2014; http://www.bbc.com/news/magazine-27503660. Accessed 1 Jan 2016.
23. Zipursky JS, Sidorsky TI, Freedman CA, et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium Difficile infection. Clin Infect Dis. 2012;55(12):1652-8. doi:10.1093/cid/cis809. [published Online First: Epub Date]
24. Pakyz AL, Moczygemba LR, VanderWielen LM, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection: The patient experience. Am J Infect Control. 2016 doi:10.1016/j.ajic.2016.01.018 [published Online First: Epub Date].
25. Brandt LJ. Fecal Microbiota Transplantation: Patient and Physician Attitudes. Clin Infect Dis. 2012 doi:10.1093/cid/cis812 [published Online First: Epub Date].
26. Dennis M, Salpeter MJ, Hota S. Low awareness but positive attitudes toward fecal transplantation in Ontario physicians. Can J Infect Dis Med Microbiol. 2015;26(1):30-2.
27. Zipursky JS, Sidorsky TI, Freedman CA, et al. Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium Difficile infection. Can J Gastroenterol Hepatol. 2014;28(6):319-24.
28. Paramsothy S, Walsh AJ, Borody T, et al. Gastroenterologist perceptions of faecal microbiota transplantation. World J Gastroenterol. 2015;21(38):10907-14. doi:10.3748/wjg.v21.i38.10907. [published Online First: Epub Date]
29. Moossavi S, Salimzadeh H, Katoonizadeh A, et al. Physicians’ knowledge and attitude towards fecal Microbiota transplant in Iran. Middle East J Dig Dis. 2015;7:155-60.
30. Friedrich MJ. Unraveling the influence of gut microbes on the mind. JAMA. 2015;313(17):1699-701.
31. Sha S, Liang J, Chen M, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther. 2014;39(10):1003-32. doi:10.1111/apt.12699. [published Online First: Epub Date]
32. Dinan TG, Stilling RM, Stanton C, et al. Collective unconscious: how gut microbes shape human behavior. J Psychiatr res. 2015;63:1-9. http://dx.doi.org/10.1016/j.jpsychires.2015.02.021 [published Online First: Epub Date]
33. Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endoscopy International Open. 2016;4(6):E610-3. doi:10.1055/s-0042-105205. [published Online First: Epub Date]
34. Nuffield Council of Bioethics. Ideas about naturalness in public and political debates about science, technology and medicine. Nuffield Council on Bioethics. 2015. http://nuffieldbioethics.org/wp-content/uploads/NCOB_naturalness-analysis-paper.pdf. Accessed 22 Dec 2015.
35. Rubin DT, Becker S, Siegler M. Ethical considerations for clinical trials in inflammatory bowel disease. Gastroenterol Hepatol. 2014;10(1):37-41.
36. Kahn SA, Rubin DT. When Subjects Violate the Research Covenant: Lessons Learned from a Failed Clinical Trial of Fecal Microbiota Transplantation. Am J Gastroenterol. 2016 doi:10.1038/ajg.2016.153[published Online First: Epub Date]|.
37. Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. Irb. 2004;26(2):1-8.
38. Caulfield T, McGuire A. Athletes’ use of unproven stem cell therapies: adding to inappropriate media hype? Mol Ther. 2012;20(9):1656-8. doi:10.1038/mt.2012.172. [published Online First: Epub Date]
39. Rubin DT, Cleveland NK, et al. Am J Gastroenterol. 2015;110(9):1252-6. doi:10.1038/ajg.2015.86. [published Online First: Epub Date]
40. Schmidt CW. The yuck factor: when disgust meets discovery. Environ Health Perspect. 2008;116(12):A524-7.
41. Chuong KH, O'Doherty KC, Secko DM. Media discourse on the social acceptability of fecal transplants. Qual Health res. 2015;25(10):1359-71. doi:10.1177/1049732314568199. [published Online First: Epub Date]
42. Godlee F, Smith J, Marcovitch H. Wakefield’s article linking MMR vaccine and autism was fraudulent. BMJ. 2011;342. doi:10.1136/bmj.c7452[published Online First: Epub Date].
43. Chehoud C, Dryga A, Hwang Y, et al. Transfer of Viral Communities between Human Individuals during Fecal Microbiota Transplantation. MBio. 2016;7(2). doi:10.1128/mBio.00322-16[published Online First: Epub Date]|.
44. Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal Microbiota transplantation. Inflamm Bowel Dis. 2015;21(7):1600-6. doi:10.1097/mib.0000000000000405. [published Online First: Epub Date]
45. Bakken JS, Borody T, Brandt LJ, et al. Fecal Microbiota Transplantation Workgroup: TreatingClostridium difficileinfection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9. doi:10.1016/j.cgh.2011.08.014[published Online First: Epub Date]|.
46. Relman DRA, Vender RJ, et al. Joint society letter to FDA - current consensus guidance on donor Screeningand stool testing for FMT. 2013.
47. Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145(5):946-53. doi:10.1053/j.gastro.2013.08.058. [published Online First: Epub Date]
48. Kazerouni A, Burgess J, Burns LJ, et al. Optimal screening and donor management in a public stool bank. Microbiome. 2015;3:75. doi:10.1186/s40168-015-0140-3. [published Online First: Epub Date]